Slow-released preparation containing hydrochlorothiazide and clonidine hydrochloride and its preparing method

A technology of clonidine hydrochloride and hydrochlorothiazide, which is applied to medical preparations containing active ingredients, medical preparations with non-active ingredients, and pharmaceutical formulas, etc. It can solve the problems of short duration of drug effects, easy to forget to take and miss doses, and blood drug concentration. Low-level problems, to achieve stable blood drug concentration in the body, reduce the number of administrations, and reduce the effects of toxic and side effects

Active Publication Date: 2009-06-03
北京合源汇丰医药科技有限公司
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the fact that the drug release of ordinary tablets is too fast, the immediate blood drug concentration is too high, and the blood drug concentration is too low after short-term metabolism.
In addition, patients need to take it more than three times a day, which is extremely inconvenient, and it is easy to forget to take and miss a dose, which will affect the curative effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow-released preparation containing hydrochlorothiazide and clonidine hydrochloride and its preparing method
  • Slow-released preparation containing hydrochlorothiazide and clonidine hydrochloride and its preparing method
  • Slow-released preparation containing hydrochlorothiazide and clonidine hydrochloride and its preparing method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] The following is the amount used in 1000 pieces

[0034] a. Hydrochlorothiazide immediate-release small tablets

[0035] Component Amount (g)

[0036] Hydrochlorothiazide 6

[0037] Microcrystalline Cellulose 10

[0038] Lactose 12.95

[0039] Crospovidone 0.9

[0040] Magnesium stearate 0.15

[0041] b. Hydrochlorothiazide extended-release small tablets

[0042] Component Amount (g)

[0043] Hydrochlorothiazide 31.5

[0044] Hydroxypropyl methylcellulose 12.5

[0045] Kabob 2

[0046] Lactose 8.725

[0047] Magnesium stearate 0.275

[0048] c. Clonidine Hydrochloride Sustained Release Small Tablets

[0049] Component Dosage

[0050] Clonidine hydrochloride 0.1125

[0051] Hydroxypropyl methylcellulose 25

[0052] Carbopol 2.5

[0053] Lactose 22.1375

[0054] Magnesium stearate 0.25

[0055] The preparation process is as follows:

[0056]The raw and auxiliary materials are crushed and sieved, mixed according to the above prescription amount, and then...

Embodiment 2

[0058] The consumption of present embodiment is the amount used by 1000

[0059] a. Hydrochlorothiazide immediate-release small tablets

[0060] Component Dosage

[0061] Hydrochlorothiazide 6

[0062] Microcrystalline Cellulose 10

[0063] Lactose 12.95

[0064] Crospovidone 0.9

[0065] Magnesium stearate 0.15

[0066] b. Hydrochlorothiazide extended-release small tablets

[0067] Component Amount (g)

[0068] Hydrochlorothiazide 31.5

[0069] Hydroxypropyl methylcellulose K100 10.2

[0070] Kabob 9.6

[0071] Lactose 19.2

[0072] Magnesium stearate 0.3

[0073] c. Clonidine Hydrochloride Sustained Release Small Tablets

[0074] Component Dosage

[0075] Clonidine hydrochloride 0.1125

[0076] Hydroxypropyl methylcellulose K100 30

[0077] Kabob 9

[0078] Lactose 10.6375

[0079] Magnesium stearate 0.25

[0080] The preparation method is the same as in Example 1.

Embodiment 3

[0082] The consumption of present embodiment is the amount used by 1000

[0083] a. Hydrochlorothiazide immediate-release small tablets

[0084] Component Dosage

[0085] Hydrochlorothiazide 6

[0086] Microcrystalline Cellulose 10

[0087] Lactose 12.95

[0088] Crospovidone 0.9

[0089] Magnesium stearate 0.15

[0090] b. Hydrochlorothiazide extended-release small tablets

[0091] Component Dosage

[0092] Hydrochlorothiazide 31.5

[0093] Hydroxypropyl methylcellulose K15 7.8

[0094] Carbopol 1.2

[0095] Lactose 19.2

[0096] Magnesium stearate 0.3

[0097] c. Clonidine Hydrochloride Sustained Release Small Tablets

[0098] Component Dosage

[0099] Clonidine hydrochloride 0.1125

[0100] Hydroxypropyl Methyl Cellulose K15 36

[0101] Kabob 21

[0102] Lactose 2.5875

[0103] Magnesium stearate 0.3

[0104] The preparation method is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention belongs to the field of medicine preparation. In the concrete, it relates to a compound medicine slow release preparation containing hydrochlorothiazide and clonidine hydrochloride. It is characterized by that said slow release preparation is composed of two portions of quick-released portion and slow-released portion. Besides, said invention also provides its preparation method and concrete steps.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a slow-release preparation of a compound drug of hydrochlorothiazide and clonidine hydrochloride, and also discloses a preparation method of the slow-release preparation. Background technique [0002] Hydrochlorothiazide is a diuretic. At the initial stage of medication, it is natriuretic and diuretic, which reduces blood volume and extracellular fluid, reduces cardiac output, and lowers blood pressure. After several weeks of continuous medication, the blood volume and cardiac output gradually recovered, and the blood pressure continued to decrease. At this time, the antihypertensive mechanism is the natriuretic and diuretic effect, which can reduce the sodium ion content in the arterial wall cells and reduce the endogenous response of vascular smooth muscle. The reactivity of vasoactive substances reduces the peripheral resistance and induces the production of vasodila...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/549A61K9/16A61K9/22A61K47/38A61P9/12A61K31/4168
Inventor 高署
Owner 北京合源汇丰医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap